|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_060838, 261878497|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||61389 Da|
|Application Notes||LMBRD1 antibody can be used for detection of LMBRD1 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Reconstitution & Storage||LMBRD1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||LMBRD1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Probable lysosomal cobalamin transporter. Required to export cobalamin from lysosomes allowing its conversion to cofactors. Isoform 3 may play a role in the assembly of hepatitis delta virus (HDV).|
|Cellular Location||Lysosome membrane; Multi-pass membrane protein|
|Tissue Location||Isoform 3 is expressed in liver.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
LMBRD1 Antibody: LMBRD1, also known as NESI (nuclear export signal-interacting protein, is a lysosomal membrane protein that is thought be involved in the transport and metabolism of cobalamin. LMBRD1 was initially identified as interacting with the large form of the hepatitis delta antigen and may be required for the nucleocytoplasmic shuttling of the hepatitis delta virus. Mutations in this gene are associated with the vitamin B12 metabolism disorder termed, homocystinuria-megaloblastic anemia complementation type F (cblF).
Gailus S, Hohne W, Gasnier B, et al. Insights into lysosomal cobalamin trafficking: lessons learned from cblF disease. J. Mol. Med.2010; 88:459-66.
Wang Y-S, Chang SC, Huang C, et al. Novel nuclear export signal-interacting protein, NESI, critical for the assembly of hepatitis delta virus. J. Virol.2005; 79:8113-20.
If you have any additional inquiries please email technical services at email@example.com.